ChemDiv Extends Partnership with Mondego Bio on PTPN2 Immuno-Oncology Program

ChemDiv announced in a press release that it has extended its discovery and early development partnership with Mondego Bio to advance a best-in-class immuno-oncology program targeting PTPN2. The extension follows Mondego Bio’s Series A financing led by Biovance Capital, with participation from OrbiMed Advisors and Torrey Pines Investment.

The collaboration builds on ChemDiv’s rational drug design approach, integrating reversible, covalent, and allosteric inhibitors to achieve selectivity, high oral bioavailability, and strong in vivo efficacy. ChemDiv’s teams in Germany, the U.S., and Portugal contributed medicinal chemistry, pharmacology, and translational biology work that advanced Mondego’s pre-IND program.

Under the extended agreement, ChemDiv will continue to provide medicinal chemistry and discovery biology support for backup series, CMC process research, and large-scale manufacturing for animal studies. The company will also offer computational and wet-lab pharmacology to accelerate the program’s clinical readiness, leveraging its AI- and ML-enabled design and translational capabilities.